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Abstract: Ziconotide (Prialt®), a synthetic version of the peptide ω-conotoxin MVIIA 
found in the venom of a fish-hunting marine cone snail Conus magnus, is one of very few 
drugs effective in the treatment of intractable chronic pain. However, its intrathecal mode 
of delivery and narrow therapeutic window cause complications for patients. This review will 
summarize progress in the development of small molecule, non-peptidic mimics of Conotoxins 
and a small number of other venom peptides. This will include a description of how some of 
the initially designed mimics have been modified to improve their drug-like properties. 
Keywords: venom peptides; toxins; conotoxins; peptidomimetics; N-type calcium  
channel; Cav2.2 
 
1. Introduction 
A wide range of species from the animal kingdom produce venom for use in capturing prey or for 
self-defense. Animal venoms typically consist of a complex mixture of proteins, peptides and small 
molecules [1]. Venom peptides in particular have been intensively studied following the discovery of 
fascinating pharmacological properties of peptides isolated from marine mollusks and terrestrial snakes 
and arthropods. The sheer number of bioactive venom peptides produced by species from the animal 
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kingdom is astronomical [1] and these represent a vast and largely untapped source of new research 
tools and therapeutic leads. Peptides found in the venom of the fish-hunting cone snails of the genus 
Conus have been the focus of considerable attention, largely due to their often powerful and selective 
modulating effects on human ion channels. While a synthetic version of one of these Conus peptides  
(ω-conotoxin MVIIA, Ziconotide (Prialt®)) is now in limited clinical use, the biophysical properties of 
peptides in general makes them unsuitable for use as drugs. Conus peptides have, however, served as 
the inspiration for a number of bioactive discovery programs where the objective is to develop  
drug-like small molecules that mimic the biological activity of the natural peptide. Presented in this 
review is a discussion of the approaches used by researchers in this area and progress to date. 
Compared to conotoxin mimics, the mimicry of venom peptides from other sources has been more 
limited. Publically disclosed efforts with snake peptides and a peptide from the sun anemone will be 
described. The most successful of all of these programs has been the development of Tirofiban 
(Aggrastat®), an anti-platelet drug used to reduce the rate of thrombotic cardiovascular events and 
inspired by a tripeptide fragment of an anti-coagulant found in the venom of the African saw-scaled 
viper Echis carinatus. 
2. Peptidomimetics 
Peptide mimics or peptidomimetics are compounds that possess similar biological activity and/or 
3D topography as a native peptide or protein fragment. Peptidomimetics typically interact with a 
biological target in a similar manner to the native peptide and as a result they exert a similar biological 
effect [2]. Peptidomimetics are commonly designed to overcome the bioavailability and instability issues 
associated with peptides and proteins. Three distinct types of peptidomimetics have been classified [3–5]. 
Type-I peptidomimetics, also known as structural mimetics, are peptide backbone mimetics, where the 
local topography is analogous to the native peptide and functionalities required to interact with the 
enzyme or receptor are present. Type-II peptidomimetics, also known as functional mimetics, interact 
with the enzyme or receptor of interest in a related way to the active peptide but are not necessarily 
structurally related to the peptide. Type-III peptidomimetics, also known as functional-structural 
mimetics, have a core scaffold structure that is different from the active peptide, and from which 
projects amino acid side chain mimics in a well-defined spatial orientation, simulating the way the 
native peptide interacts with the biological target.  
One approach to the development of type-III mimetics involves the mimicry of the α,β-bond vectors 
of the amino acid residues responsible for a peptide’s biological activity. This method was 
promulgated by Bartlett and Lauri [6] and is the fundamental tenet of the Computer-Assisted Vector 
Evaluation and Target Design (CAVEAT) program [7]. Much of the biological activity elicited by an 
active peptide results from the interaction of the side chain termini with the receptor, and when 
detailed structural information about this interaction is absent, it is very difficult to predict the exact 
spatial orientation of these termini when bound. The position and direction of the first side chain bonds 
that project from the peptide backbone, the α,β-bond vectors, are however, usually much better 
defined. If a reliable solution state structure or computational model of the peptide is available, the  
α,β-bond vector approach can be used to design type-III mimetics. At their core, these compounds have 
a semi-rigid molecular scaffold from which bonds that are positioned to simulate the location and 
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direction of the α,β-bond vectors of the key amino acids side chains on the active peptide are projected. 
Amino acid side mimics are attached to α,β-bond replicas with the expectation that, as with the active 
peptide, the termini of these functionalities will find the desired binding site within the receptor. 
3. Pain Blocking Conotoxins and Their Mimetics 
3.1. Conotoxins 
Conotoxins are neurotoxic peptides isolated from the venom of marine cone snails from the genus 
Conus. To date over 700 species from this genus have been described, with the venom of each 
containing a unique and diverse mixture of pharmacologically active compounds [8–11]. Conotoxins 
are small, structurally defined peptides that range in size from eight to thirty amino acid residues and 
typically have one or more disulfide bonds. The fish-hunting cone snails have the most poisonous 
venom and there have been over 30 deaths as a result of cone snails envenomation [10]. The majority 
of these deaths are due to the cone snail Conus geographus, whose sting can cause paralysis within  
30 min and coma or death within five hours [12]. Interestingly, in these unfortunate cases the victim 
has been reported to die a “painless death” [10]. The potency and analgesic activity of the Conus 
venoms has motivated a number of research groups to isolate and identify the pharmacologically active 
components in the venom, with Olivera and coworkers being pioneers in this field. There are a number 
of excellent reviews that summarize this research [13–17]. The comprehensive pharmacology of 
conotoxin peptides [9,10,16–22] has also been comprehensively reviewed, and hence will not be 
described here in detail.  
The nomenclature for conotoxins was first proposed in 1985 [23] and further refined in 1988 [15]: 
When the conotoxin has a known mode of action, then a Greek letter prefix is used to designate its 
pharmacological action. This is then followed by “-conotoxin”, a one or two letter code to assign the 
Conus species, a Roman numeral to indicate the Cys arrangement and finally an upper case letter that 
allows conotoxins of the same class, isolated from the same species, to be differentiated [13,15,23].  
For example, ω-conotoxin GVIA targets voltage gated calcium channels (ω), is a peptide from the 
Conus species Conus geographus (G) and has a class VI Cys pattern (C–C–CC–C–C). Conotoxins of 
particular relevance to this article are the ω-conotoxins and μ-conotoxins. More recently conotoxins 
have been classed according to their superfamily. Peptides within a superfamily have a highly 
conserved amino acid sequence and share the same disulfide connectivity [24,25]. The ω-conotoxins 
belong to the O1-superfamily of which κ-, δ-, and µO-conotoxins are also members, and the  
μ-conotoxins are members of the M-superfamily. For a recent review on conotoxin gene superfamilies, 
see Robinson and Norton [26]. 
ω-Conotoxins contain six Cys residues and three disulfide bridges. To date 21 ω-conotoxins 
peptides have been identified with net charges ranging from +5 to +7 [21,27,28]. The most well 
studied ω-conotoxins are the N-type calcium channel (Cav2.2) blockers MVIIA and GVIA, and the 
P/Q-type calcium channel (Cav2.1) blocker CVID. The amino acid sequences of these peptides are 
shown in Figure 1 as well as the sequence of MVIIC, a Cav2.1 blocker. The backbone structure of  
ω-conotoxins MVIIA, GVIA and CVID, determined from Nuclear Magnetic Resonance (NMR) 
spectroscopy experiments, are shown in Figure 2. 
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Figure 1. Single letter amino acid sequences of ω-conotoxin MVIIA, MVIIC, CVID and 
GVIA; disulfide bridges are indicated by solid lines, O = hydroxyproline. 
 
Figure 2. Three-dimensional structures of ω-conotoxins that are relevant to this review.  
The peptide backbone structure is shown as a yellow tube, the side chain residues are 
shown as thin tubes and are colored according to the atom type, and hydrogen atoms are 
not shown. The amino acid side chains thought to be important for biological activity are 
highlighted. (a) ω-conotoxin GVIA (PDB code: 2cco); (b) ω-conotoxin MVIIA  
(PDB code: 1ttk); and (c) ω-conotoxin CVID (coordinates obtained from reference [29]).  
Voltage-gated calcium ion channels (VGCC) control a number of physiological functions including 
chronic and neuropathic pain. For recent reviews on the topic see references [30–37]. VGCC can be 
broadly divided into two classes; the low-voltage activated and high-voltage activated channels. The  
N-type (Cav2.2) and P/Q-type calcium channels (Cav2.1) are members of the high-voltage activated 
channels with the ω-conotoxins selectively targeting these channels. The ability of conotoxins such as 
MVIIA, GVIA and CVID to selectively block Cav2.2 channels is of significant interest as these 
channels are implicated in refractory pain states such as neuropathic pain. By contrast, Cav2.1 channels 
occur at the neuromuscular junction and the inhibition of these channels can produce a number of 
nasty pathological effects. ω-Conotoxin MVIIC is known to inhibit Cav2.1 channels. 
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Μ-Conotoxins contain six Cys residues, three disulfide bridges, and have a class III Cys pattern  
(CC–C–C–CC). To date, 20 μ-conotoxins peptides have been identified [38]. μ-Conotoxins selectively 
block voltage-gated sodium channels (VGSCs).  
3.2. Commonly Used Assays 
Before discussing the development of conotoxin mimetics as potential pain blockers, a summary of 
typical bioassays used to assess these mimetics is presented here. 
3.2.1. Rat Vas Deferens 
It has been shown that the twitch contractions of the rat vas deferens, in response to electrical field 
simulation, are controlled by release of neurotransmitters governed by the Cav2.2 channel [14,18,39]. 
These electrically induced muscle contractions are inhibited by ω-conotoxin GVIA and it is proposed 
that this is due to the peptide binding to the presynaptic sites on the Cav2.2 channels [14,18,39]. 
Consequently, this assay was used in early studies to assess the structure–function of ω-conotoxin  
GVIA [40,41] and CVID [42], and the potency of peptidomimetics of ω-conotoxin GVIA [43]. 
3.2.2. Radioligand Displacement Assay 
The radioligand binding assay was first used by Snyder and coworkers in 1988 to characterize the 
binding of ω-conotoxin GVIA in the brain, using membranes from rat brains and 125I-labeled  
ω-conotoxin GVIA [44]. This technique has been extended to the development of a radioligand 
displacement assay, which can be used to gauge the ability of compounds to bind to rat brain Cav2.2 
channels [45]. After the preparation of crude rat brain membrane, the labeled peptide and a range of 
ligand concentrations are added [45], and a dose-response is then determined by counting the residual 
125I-labeled ω-conotoxin GVIA that remains associated with the membrane. The binding affinity of 
small molecule mimetics of ω-conotoxin GVIA to the Cav2.2 channel has been determined by this 
method [46–51]. It is assumed that a compound that is able to displace 125I-labeled ω-conotoxin GVIA 
from rat brain membrane does so by binding to the same part of the Cav2.2 ion channel as GVIA and 
hence should have the same pain-blocking effect. This may not always be true as other factors such as 
allosteric effects could cause the labeled GVIA to be released from the brain membrane. Nonetheless, 
this assay has served as a useful initial screen for Cav2.2 channel affinity and has led to the discovery 
of compounds with functional activity in, for example, electrophysiological assays.  
3.2.3. FLIPR assay with SH-SY5Y Neuroblastoma Cells 
In recent years a functional FLIPR (Fluorescence Imaging Plate Reader) assay has replaced the 
radioligand displacement assay as the high-throughput assay of choice for the screening of Cav2.2 
blockers. Neuroblastoma cells are a good cellular model for monitoring VGCC [52]. The magnitude of 
intracellular calcium flux elicited by the addition of KCl and CaCl2 is determined by measuring the 
change in fluorescence of a calcium-sensitive dye and can be used to gauge the level of inhibition of 
calcium channels by added compounds. For Cav2.2 inhibition studies, SH-SY5Y neuroblastoma cells 
that endogenously express human Cav2.2 channels in a physiologically relevant context, are briefly 
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incubated with varying concentrations of the compounds of interest, in the presence of saturating 
concentrations of the L-type calcium channel blocker nifedipine. The Ca2+ responses produced by  
KCl-depolarization are measured and dose-response curves enable calculation of IC50 values [51,53,54]. 
The major drawbacks of the radioligand displacement assay—The requirement for radioisotopes and 
the fact that it is not a functional assay—are negated with the FLIPR assay. Furthermore, the FLIPR 
assay results are reported to be a better predictor of activity in electrophysiological assays (for information 
on electrophysiological methods see below). Estimated IC50 values for the functional inhibition of 
calcium channels obtained from the FLIPR assay and electrophysiology experiments have, in some 
cases, been observed to be in close agreement, whereas the IC50 values obtained from the radioligand 
displacement assay can over estimate functional activity by up to an order of magnitude [51]. 
3.2.4. IMR-32 Human Neuroblastoma Cell Assay 
IMR-32 human neuroblastoma cells were first used to investigate the binding of ω-conotoxins to 
VGCC in 1988 (see reference [55] and later references [52,56]). The IMR-32 human neuroblastoma 
cell assay has some similarities to the SH-SY5Y neuroblastoma cell assay described above, both are 
fluorescent based assays, intracellular calcium flux elicited by the addition of K+, and both assays 
include the L-type calcium channel blocker nifedipine. To date, there is only one report of this assay 
being used to determine the binding affinity of small molecule mimics of an ω-conotoxin and in this 
assay Indo-1 is used as the indicator [57].  
3.2.5. Electrophysiological Methods—Patch Clamp Technique 
Electrophysiological methods have long been considered the “gold-standard” technique for studying 
ion channels. In the patch clamp technique, whole cell electrophysiological recordings are made using 
a glass micropipette electrode that is “clamped” to the surface of a cell expressing the ion channel of 
interest. For voltage gated ion channels like Cav2.2, the channel can be cycled from the resting to the 
activated state by varying the electrical potential from a holding potential of ~−80 mV to more 
depolarized test potentials, and the current generated under the voltage clamp measured. The inhibition 
of such channel currents by potential channel blocking compounds can be observed by adding the 
compounds to the extra-cellular solution. Dose responses can be used to assess the relative 
effectiveness of channel blockers. Since the patch clamp technique can be used to cycle voltage-gated 
ion channels through resting, depolarized and inactivated forms, a compound’s effect on each of these 
states can be measured. This information can be used to optimize compounds for particular channel 
states relevant to certain disease pathologies like, for example, neuropathic pain.  
3.3. ω-Conotoxin Mimetics 
3.3.1. ω-Conotoxin MVIIA 
The first report of a low molecular weight type-III peptidomimic of ω-conotoxin MVIIA was by the 
group of Horwell from Parke-Davis (now Pfizer) [58]. The 1H NMR solution structure of the peptide 
revealed the backbone structure of the peptide [59] and it was known that the residues required for 
binding were Lys2, Arg10, Leu11, Tyr13 and Arg21 (Neurex Corporation) [60]. Utilizing this information, 
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Horwell et al. designed a dendritic scaffold that would enable the mimicry of three key amino acid 
residues [Arg10, Leu11 and Tyr13]. The first generation compound, the synthesized alkylphenyl ether 
(compound 1 in Figure 3) based on a phloroglucinol core [58], gave poor inhibition (19% at 10 μM) in 
an N-type IMR-32 human neuroblastoma cell assay [57]. The second generation compounds (2 and 3), 
whose design was also supported by molecular modeling, gave improved activity (IC50 values of 3.3 
and 2.7 μM) [57]. This report was one of the first to use in silico design to assist with the construction 
of active compounds, thereby enabling the pharmacophore of the native peptide to be better replicated. 
The flexibility of the projected residues in these mimics was integral to their design as it was expected 
that their fluxional nature would allow them to “sample” a wider region of conformational space and 
hence would be more likely to able to adopt an optimal ion channel binding conformation. 
 
Figure 3. Non-peptide mimetics containing a dendritic scaffold. The dendritic scaffold is 
highlighted in blue. IC50 values are for Cav2.2 activity in the IMR-32 assay [57,58]. 
In a follow-up report, three dendroid molecules were synthesized using the core of  
8-hydroxy-2-(1H)-quinolinone attached to a 5-hydroxymethyl resorcinol (4–6, Figure 4) [61]. While 
these compounds were designed to be mimics of ω-conotoxin MVIIA, their ability to inhibit Cav2.2 
channels has not been reported.  
 
Figure 4. Non-peptide mimetic of ω-conotoxin MVIIA, using the scaffold core of  
8-hydroxy-2-(1H)-quinolinone and 5-hydroxymethyl resorcinol. The scaffold core is 
highlighted in green [61]. 
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3.3.2. ω-Conotoxin CVID 
It has been shown that Leconotide, a synthetic version of CVID (also known as AM336 and 
CNSB004), is the most selective ω-conotoxin for the N-type (Cav2.2) over the P/Q-type (Cav2.1) 
calcium channel with 700,000-fold selectivity observed [42]. Furthermore, the native peptide has been 
shown to have a wider therapeutic window than Ziconotide (Prialt®) and has fewer cardiovascular side  
effects [62,63]. Lewis and coworkers developed small molecule cyclic pentapeptides as type-I mimics 
of ω-conotoxin CVID [64]. The 1H NMR solution structure of ω-conotoxin CVID showed that  
this conotoxin has two hydrogen bonds between loop 2 and 4 that stabilize loop 2 and provide extra 
rigidity [42]. Lewis and coworkers determined the Cα–Cβ vectors of the residues believed to be 
required for binding to the Cav2.2 channel, concentrating on residues 9–14 that are found in  
loop 2 [64]. Simplification of this pharmacophore to the Cα–Cβ of residues 9–14 enabled virtual 
screening of a library of compounds and identification of the cyclic pentapeptide framework containing 
one or more D-amino acids (Figure 5). In total, twenty cyclic pentapeptides of this first series were 
synthesized and tested for their binding affinity to the Cav2.2 channel using the radioligand displacement 
assay with 125I-GVIA. Two analogues [c-AKlMy] and [c-aKlMY] (L-amino acids are shown as 
uppercase letters and D-amino acids are represented by lowercase letters), gave IC50 values of 40 and 
60 μM respectively. Based on these results a second series was designed and tested. This series,  
[c-KlPyK], [c-lKPyK] and [c-lPKyK], had improved rigidity due to the introduction of a proline 
residue and also possessed a second positive charge through the inclusion of a second lysine residue. 
The IC50 values for the second series of peptides ranged from 16 to 480 μM. The most potent analogue 
was [c-KlPyK] (compound 7 in Figure 5, IC50 = 16 μM). These compounds were also tested for their 
selectivity for N-type (Cav2.2) over the P/Q-type (Cav2.1) voltage gated calcium channel by testing 
their binding affinity in the radioligand displacement assay with 125I-MVIIC. ω-Conotoxin MVIIC is 
known to inhibit Cav2.1. None of the peptides were found to displace 125I-MVIIC at concentrations 
below 300 μM and it was thus concluded that these cyclic peptides were selective for N-type voltage 
gated calcium channels. 
 
Figure 5. (a) Diagram of the three-dimensional structure of ω-conotoxin CVID with 
sidechains of residues 9–14 shown, coordinates obtained from reference [29].  
(b) Backbone and sidechains of residue 9–14 alone; (c) Structure of [c-KlPyK] 7, the most 
potent analogue discovered (L-amino acids are shown as uppercase letters and D-amino 
acids are represented by lowercase letters). The IC50 value was determined using the 
radioligand displacement assay with 125I-GVIA [64]. 
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As the cyclic pentapeptides discussed above mimic the binding of ω-conotoxin CVID and are 
selective against for N-type calcium channels, there was great hope that small molecules could be 
designed and developed to mimic ω-conotoxin CVID. However, since this original report by Lewis 
and coworkers in 2004 [64] there have been no further reports of CVID peptidomimetics.  
3.3.3. ω-Conotoxin GVIA 
Of all the ω-conotoxins, ω-conotoxin GVIA has been the subject of the most reports of type-III 
mimetics, firstly by the group of Baell and more recently from the group of Duggan and Tuck. The 
initial report of a type-III GVIA peptidomimetic was by Baell et al. in 2001 [43]. Three non-planar, 
rigid scaffolds were designed using the data from the NMR solution structure of ω-conotoxin GVIA, 
utilizing the Cα–Cβ bond vector approach combined with interactive de novo design. It was known that 
the residues Lys2 and Tyr13 were crucial for potency and to a lesser extent the residues Arg17, Tyr22 
and Lys24 [40]. With this in mind, Baell et al. concluded that a three-point mimic must include Lys2 
and Tyr13, but it was unclear which of the remaining three residues should be included. Guided by 
molecular modeling and scaffold design, it was decided that the third residue would be Arg17. 
Mimetics based on two out of the three proposed scaffolds, the benzothiazole derivative 8 and the 
anthranilamide derivative 9, were synthesized and were found to have activity in the rat vas deferens 
assay, with IC50 values of 68 μM and 98 μM, respectively, being obtained (see Figure 6 for relevant 
compound structures). Subsequent testing of these compounds for Cav2.2 activity using the radioligand 
displacement assay with 125I-GVIA gave the IC50 values of 1.9 μM [46] and 3.5 μM [47], respectively. 
An overlay of the benzothiazole and anthranilamide core scaffolds respectively with the NMR solution 
structure of ω-conotoxin GVIA is shown in Figure 7. This figure demonstrates that the benzothiazole 
mimetics and the anthranilamide mimics possess the correct geometry to ensure that the side chain 
mimics are positioned to replicate the location and direction of the α,β-bond vectors of the key amino 
acids side chains. 
 
Figure 6. Initial type-III peptidomimetics of ω-conotoxin GVIA. Cav2.2 activity was 
determined using the rat vas deferens assay [43] and later using the radioligand displacement 
assay with 125I-GVIA [46,47]. The core scaffold is colored blue.  
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Figure 7. Backbone structure of ω-conotoxin GVIA (yellow) with the amino acid side 
chains Lys2, Tyr13, Arg17 shown in teal; (a) overlaid with a model of the benzothiazole  
mimetic 8 [28]—Reproduced with permission; and (b) overlaid with X-ray crystal 
structure of the anthranilamide scaffold core without side chain mimics. The α,β-bond vectors 
are shown in purple and the bonds mimicking the α,β-bond vectors are shown in  
yellow [47]—Reproduced with permission. 
Encouraged by the activity of benzothiazole derivative 8 and the anthranilamide derivative 9, Baell, 
Duggan and coworkers synthesized analogues of both in order to start to build up structure-activity 
relationships [46,47]. Three benzothiazole analogues were tested for their binding affinity to the 
Cav2.2 channel using the radioligand displacement assay with 125I-GVIA. The structures of two 
analogues are shown in Figure 8 [46]. Conversion of the original Tyr side chain to a Phe mimic, by 
removal of the phenolic OH group, gave compound 10, which resulted in a negligible loss of activity 
(Figure 8). Limited activity loss was also observed when the guanidinium moiety was truncated to a 
primary amine (compound 11). Interestingly, these benzothiazole analogues (8, 10 and 11) showed a 
20–25-fold selectivity for the N-type (Cav2.2) over the P/Q-type (Cav2.1) voltage gated calcium 
channel. In the anthranilamide series, truncation of the guanidinium to the primary amine was also 
investigated (Figure 8) [47]. Compound 9 was 30-fold more selective for Cav2.2 over Cav2.1.  
A negligible loss of activity was observed for 12 and this analogue was observed to be 13-fold selective 
for Cav2.2 over Cav2.1. 
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Figure 8. Exploration of the benzothiazole and anthranilamide scaffolds, Cav2.2 activity 
was determined using the radioligand displacement assay with 125I-GVIA [46,47]. The 
scaffold core is colored blue. 
Further investigation of the benzothiazole scaffold by Duggan and Tuck resulted in the synthesis of 
the truncated analogues 13–16 [50]. Previous work had shown that rotation around the N-benzyl bond 
resulted in two main conformations; the Arg17 side chain mimic could point up or down with respect 
to the benzothiazole ring and hence this side chain had the potential to mimic the Lys2 side chain of 
GVIA. Truncation of compound 10 resulted in analogues that have a significantly lower molecular 
weight, and could be synthesized in 6–7 fewer steps (Figure 9). However, the truncated Tyr13-Lys2 
mimic 13 was found to be inactive. The corresponding guanidylated compound 14 showed improved 
activity, however this was still ten-fold lower than that of the three-point mimic 10. Conversely, the 
truncated Tyr13-Arg17 mimic 15 showed comparable activity to the parent analogue 10, though taking 
the guanidinium functional group back to a primary amine (compound 16) resulted in a significant loss 
of activity. This finding confirmed the important contribution that the guanidinium group makes to the 
observed activity of these benzothiazole compounds and showed that the truncated mimic, a two-point 
mimic, could have comparable activity to a more complex, higher molecular weight compound.  
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Figure 9. Truncation of the original benzothiazole scaffold 10 resulting in two-point 
mimetics 13–16. Cav2.2 activity was determined using the radioligand displacement assay 
with 125I-GVIA [50].  
Additional work by Duggan and Tuck led to the synthesis of two amino-anthranilamide analogues 
that incorporate an amide linkage in the Arg17 mimic rather than the ether linkage (compounds 17 and 
18, Figure 10). However, while Cav2.2 activity was retained, the potency was relatively weak and as 
such no further analogues of this type were investigated [48]. It was noted that long-chain aliphatic 
amines like dodecylamine had strong calcium channel affinity [65], and in light of this Duggan and 
Tuck undertook a comprehensive study into the structure activity relationship (SAR) relevant to the 
alkyl chain length of the anthranilamide derivative 12. By varying the alkyl length of the ether and 
amide it was discovered that the optimum linker length was n = 3 and n = 7, respectively, although 
other linker lengths were well tolerated. They also explored removal of the p-hydroxyl substituent in 
12 and replacement of the p-hydroxyl substituent with a p-fluoro substituent [49]. Fluorine, a hydroxyl 
surrogate, is advantageous as phenoxy groups are very quickly metabolized in the liver and 
replacement of the phenoxy group with fluorine prevents this metabolism. This study also investigated 
if a single guanidinium group was required for good activity or if diguanidinylated compounds were 
appropriate. It was found that the diguanidinylated compounds were the most active, deletion of the 
hydroxyl substituent had little influence on activity and the analogue with the p-fluoro substituent was 
the most active compound prepared. 
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Figure 10. Exploration of the anthranilamide scaffold, only selected compounds are 
shown. Cav2.2 activity was determined using the radioligand displacement assay with  
125I-GVIA [48,49]. 
Recognizing that effective voltage-gated calcium channel blockers Z160, a reformulated form of 
NP118809 [66], and Abbott’s A-1048400 [67] contain a diphenylmethylpiperazine moiety, Duggan 
and Tuck investigated substitution of the phenoxyaniline substituent with diphenylmethylpiperazine in 
the anthranilamide class of compounds [51]. Such a replacement was expected to limit the toxicity of 
these compounds. A number of analogues were synthesized and tested for their ability to block 
neuronal calcium channels in non-functional and functional assays (Figure 11). This was the first 
report that compared the Cav2.2 activity determined using the radioligand displacement assay, the 
FLIPR assay (fluorescence-based calcium response assay with SH-SY5Y neuroblastoma cells) and a 
whole-cell patch clamp electrophysiology assay. Pleasingly, the mimetics identified to be active in the 
radioligand displacement assay were also found to elicit functional inhibition of intracellular calcium 
responses in SH-SY5Y neuroblastoma cells and calcium currents in HEK293 cells stably expressing 
human Cav2.2 channels. These results justify the overall approach employed here to identify selective 
Cav2.2 channel blockers—Which used the structure of ω-conotoxin GVIA to design inhibitors and the 
125I-GVIA radioligand displacement assay as an initial screening tool for Cav2.2 activity.  
In a recent study, Duggan and Tuck investigated molecular modifications of the anthranilamides,  
in the hope of improving physiochemical properties while maintaining Cav2.2 activity. The  
anthranilamide-based mimetics were simplified by deletion of one of the amino side chain mimics and 
the influence of the substitution pattern of the central aromatic ring was explored [54]. Compounds 
29–34 (Figure 12) were evaluated for their ability to inhibit Cav2.2 calcium responses in SH-SY5Y 
cells. Compound 30 has been tested for its ability to block calcium currents in HEK293 cells stably 
expressing human Cav2.2 channels, giving an IC50 of 36 µM [54]. The mode of action of this set of 
compounds is being further investigated in patch clamp electrophysiology experiments, and these 
results will be reported in the near future.  
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Compd. No. R1 R2 
Radioligand 
Displacement 
Assay IC50 (μM) 
SH-SY5Y 
Neuroblastoma 
Cells IC50 (μM) 
HEK293  
hCav2.2 + β3 + α2δ1 
IC50 (μM) 
25 H NH2 214 160 232 
26 H N=C(NH2)2 12 206 299 
27 F NH2 65 286 288 
28 F N=C(NH2)2 16 156 156 
Figure 11. Further exploration of the anthranilamide class of compounds where the 
phenoxyaniline substituent has been replaced with a diphenylmethylpiperazine moiety [51]. 
 
Figure 12. Truncation and SAR exploration of the anthranilamide scaffold. Cav2.2 activity 
was determined using the FLIPR SH-SY5Y neuroblastoma cells assay [54].  
3.4. μ-Conotoxin Mimetics 
μ-Conotoxin KIIIA, from Conus kinoshitai, is a 16 residue, three-disulfide bridged, peptide that 
blocks several voltage-gated sodium channel isoforms and has been shown to have potent analgesic 
activity in the mouse model for pain [68,69]. Structure–function activity studies determined that the 
key residues required for KIIIA’s activity against voltage-gated sodium channels were Lys7, Trp8, 
Arg10, Asp11, His12, and Arg14 [69]. Additionally, the solution NMR structure of μ-conotoxin KIIIA 
revealed that 5 of the 6 key residues (the exception was Arg14) were located on an α-helix. It was thus 
concluded that the α-helix plays an important role in the interaction of μ-conotoxin KIIIA with the 
voltage-gated sodium channels [70,71]. Recently type-III peptidomimetics of μ-conotoxin KIIIA have 
been designed with the aid of an in silico de novo strategy [72]. Using the Cα–Cβ bond vector approach 
Baell and coworkers devised a diketopiperazine carboxamide scaffold that would mimic the Cα–Cβ 
bond vectors of the residues Lys7, Trp8 and His12. A key part of the design is the use of the amide 
link to the His12 mimic, thus resulting in an internal H-bond that causes the molecule to adopt the 
conformation required to correctly mimic the Cα–Cβ bond vectors of the His12 sidechain. In this study 
two such mimetics were synthesized (compounds 35 and 36, Figure 13) and tested for their ability to 
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block the Nav1.7 channel (patch clamp assay). While both compounds only weakly blocked the Nav1.7 
channel they are the first type-III peptidomimetics developed based on the native structure of  
μ-conotoxin KIIIA. It was reported that peptidomimetic 35 will serve as a template for future studies.  
A second scaffold, which has a relatively simple design, was developed to mimic the Arg10 and Arg14 
residues in μ-conotoxin KIIIA [73]. Compound 37 blocked the Nav1.7 channel relatively weakly.  
 
Figure 13. Non-peptide mimetics of μ-conotoxin KIIIA by Baell and coworkers.  
The diketopiperazine carboxamide scaffold is highlighted in blue in 35 and 36. Activity is 
block of the Nav1.7 channel (patch clamp assay) [72,73]. 
4. Snake Venom Peptides and Their Mimetics 
4.1. Echistatin 
Tirofiban (Aggrastat®, MK-0383; L-700,462, 38 Figure 14) a small molecule peptidomimetic 
antiplatelet drug, was discovered by researchers from Merck in the early 1990s [74–79] and granted 
FDA approval in 1998. The development of Tirofiban was based on the 3D-structure of Echistatin 
(disintegrin), which is a derivative of an anticoagulant found in the venom of the African saw-scaled 
viper Echis carinatus. Researchers from Merck designed small molecule mimetics of the cell adhesion 
motif RGD (Arg-Gly-Asp), which was identified as the recognition element required for the 
antiplatelet activity possessed by Echistatin. Merck’s in-house sample collection was searched for 
compounds that had carboxylate and amino functionalities separated by distances of 10–20 Å.  
The latter corresponds to the approximate distance between the termini of the Arg and Asp side chains 
in RGD. Tirofiban was the end result of optimization of the initial hit from this screen [74,75].  
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Figure 14. The chemical structure of Tirofiban 38. 
4.2. Erabutoxin B 
Erabutoxin B, found in the venom of the broad-banded blue sea snake, is a 62 amino acid protein 
bearing four disulfide bridges. It has high affinity for the post-synaptic nicotinic acetylcholine receptor 
(nAChR) [80,81]. Compounds that act on the nAChR have the potential to be treatments for nicotine 
addiction, to relieve the effects of Alzheimer’s disease or be muscle relaxants. Kahn and coworkers 
utilized the X-ray structure of erabutoxin B [82,83], and the knowledge that residues 31–34 (Asp, Phe, 
Arg, Gly) that form a β-turn are essential for binding to the nAChR, to design a type-III erabutoxin 
mimetic [84], guided by molecular modeling. This led to the hexahydro-indolizinone scaffold being 
chosen as the mimetic core. The side chain residues of Asp31 and Arg33 in erabutoxin B were 
appropriately mimicked as either a carboxylate or an ammonium salt respectively (compound 39,  
Figure 15). This seminal work is the first report of molecular modeling guided design of a small 
molecule mimic of a peptide or protein found in the venom of snakes or cone snails. Unfortunately,  
no biological evaluation of this mimetic has been reported and hence it is unclear if this is a true  
type-III mimetic of erabutoxin.  
 
Figure 15. The chemical structure of an erabutoxin mimic 39. 
5. Sun Anemone Toxin 
Stichodactyla toxin (ShK), from the sea anemone Stichodactyla helianthus, is a 35 residue peptide 
that binds strongly to a number of voltage gated potassium channels [85]. The peptide has three 
disulfide linkages that produce a structurally well-defined molecule. ShK is known to have three 
separate binding sites [86,87]. The determination of the NMR solution structure allowed mapping of 
the potassium channel binding surface and thus identified the residues responsible for binding [88]. 
The toxin was found to contain a discontinuous (Arg11 and Phe27) and contiguous (Lys22, Tyr23 and 
Arg24) binding surface but its rigid nature makes it an attractive target for the rational design of  
type-III mimetics. Baell et al. utilized the previously mentioned the α,β-bond vector approach to devise 
suitable mimetics. Initially, the contiguous residues (Lys22, Tyr23 and Arg24) were investigated with 
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a core N-benzylhydantoin scaffold. For synthetic simplicity, the Tyr sidechain mimic was replaced 
with a Phe mimic, as it was known that the OH group of Tyr23 is not required for binding [86]. This 
initial compound was inactive (structure not shown), presumably because the hydantoin ring orientates 
the phenyl ring (Tyr23 mimic) in an orientation that it is perpendicular to the way Tyr23 is displayed 
in the ShK toxin [89]. Subsequently the Lys22-Tyr23-Arg11 pharmacophore was investigated using a 
quinoxaline-dione ring, however this compound was also inactive [89]. Use of the 1,7-disubstituted  
2-aminobenzimidazole core with appropriate functionalization allowed the development of 
hydroxylated and unhydroxylated compounds 40 and 41 (Figure 16). These compounds showed the 
same activity in voltage-gated Kv1.3 potassium channels patch clamp assay, thus confirming that the 
OH group of Tyr23 is not required for binding. The biological results from the first generation of 
compounds enabled pharmacophore-based database mining. Three nonpeptide hits were subsequently 
tested for activity, but were found to be inactive. While these first generation molecules were relatively  
weak binders, Baell and coworkers “built on” these results with their second-generation 
peptidomimetics [90]. For this study, they focused on the contiguous residues (Lys22, Tyr23 and 
Arg24), thus allowing for a smaller mimetic. Again, using the α,β-bond vectors of the Lys22 and 
Tyr23 side chains from the NMR solution structure of ShK, an N-alkylated indole-7-carboxamido 
scaffold was designed (compound 42). Further derivatization at the 4-position allowed for additional 
mimicry of the Arg24 sidechain residue. The activity of this compound was marginally better than that 
observed for the first-generation mimetics. It was noted that the production of a library of mimetics based 
around this the indole might lead to compounds with improved activity. 
 
Figure 16. Peptidomimetics of ShK that contain the (a) 2-aminobenzimidazole  
scaffold, compounds 40 and 41 [89]; and (b) the N-alkylated indole-7-carboxamido 
scaffold, compound 42 [90]. The scaffold structure is highlighted in blue. Activity was 
determined using a voltage-gated Kv1.3 potassium channels patch clamp assay. 
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6. Summary and Conclusions 
The stupendous number of pharmacologically active substances present in animal venoms is a 
largely untapped source of new bioactives. Peptides form a significant component of these actives but 
due to problems associated with their bioavailability, these compounds have rarely reached the clinic. 
The development of lower molecular weight organic compounds that mimic the action of some of 
these peptides—Peptidomimetics—has been one approach aimed at overcoming bioavailablity 
problems. Peptides found in the venom from the Conus marine snails have received by far the most 
attention in this regard. This has largely focused on the mimicry of the neuronal calcium ion channel 
blocking ability of the ω-conotoxins. The ω-conotoxins are exquisitely selective and potent modulators 
of voltage gated calcium ion channels and the design and construction of small molecules that 
approach the activity of these peptides has been a challenging task. Nonetheless, progress has been 
made with ω-conotoxin GVIA mimics, with the most recently developed compounds showing 
considerable promise. Mimicry of active peptides from snake and anemone venom has also been 
undertaken. The initial hit that led to the antiplatelet drug Tirofiban was inspired by an active peptide 
found in the venom of the broad-banded blue sea snake. 
There are numerous avenues to the discovery of hits with the potential to be developed into potent 
bioactives, including the screening of natural and synthetic compound collections, analoging of known 
drugs and fragment-based approaches. Where little is known about the structure of the biological 
target, which is the case with many neuronal ion channels, the mimicry of venom peptides remains an 
attractive option that is expected to be fruitful for many years to come. 
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